Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5146-5157

  Hartmann, Christian ^a,b   Hentschel, Bettina ^c   Simon, Matthias ^d   Westphal, Manfred ^e   Schackert, Gabriele ^f   Tonn, Jörg C ^g   Loeffler, Markus ^c   Reifenberger, Guido ^h   Pietsch, Torsten ^d   Von Deimling, Andreas ^b   Weller, Michael ⁱ  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PROCARBAZINE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MOLECULAR GENETICS; MUTANT; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL RATE; SURVIVAL TIME; TP53 GENE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; SURVIVORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84884582587     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0017     Document Type: Article

References (34)

1. Louis DNInternational Agency for Research on Cancer. WHO classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer; 2007.
2. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009;27:5743-50.
3. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain 2007;130:2596-606.
4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY) 2008;321:1807-12.
5. Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia 2011;59:1200-4.
6. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597-602.
7. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol 2009;118:469-74.
8. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol 2009;11:341-7.
9. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002-7.
10. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4.
11. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:653-6.
12. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
13. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009;15:6683-93.
14. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A. Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 2011;37:428-30.
15. Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, et al. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011;6:115.
16. Song Tao Q, Lei Y, Si G, Yan Qing D, Hui Xia H, Xue Lin Z, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012;103:269-73.
17. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-18.
18. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
19. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutaratedependent dioxygenases. Cancer Cell 2011;19:17-30.
20. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-8.
21. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
22. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479-83.
23. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 2012;124:547-60.
24. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009;27:5881-6.
25. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874-80.
26. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-94.
27. Stander M, Peraud A, Leroch B, Kreth FW. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 2004;101:1028-35.
28. Steinbach JP, Blaicher HP, Herrlinger U, Wick W, Nagele T, Meyermann R, et al. Surviving glioblastoma for more than 5 years: the patient's perspective. Neurology 2006;66:239-42.
29. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
30. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425-37.
31. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
32. Barbus S, Tews B, Karra D, Hahn M, Radlwimmer B, Delhomme N, et al. Differential retinoic acid signaling in tumors of long-and short-term glioblastoma survivors. J Natl Cancer Inst 2011;103:598-606.
33. Donson AM, Birks DK, Schittone SA, Kleinschmidt-De Masters BK, Sun DY, Hemenway MF, et al. Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish longterm from short-term survivors. J Immunol 2012;189:1920-7.
34. Shinawi T, Hill VK, Krex D, Schackert G, Gentle D, Morris MR, et al. DNA methylation profiles of long-and short-term glioblastoma survivors. Epigenetics 2013;8:149-56.